David E. Wheadon

David E. Wheadon (senior executive) discloses dealings in 5 companies, chiefly Sotera Health Co, Vaxart, Inc. and Indivior Pharmaceuticals, Inc. Between 28 May 2021 and 16 July 2026, the trades on record add up to 15 filings.

Purchases make up the whole of the open-market record (1 purchase, €54k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 13 share grants. So far in 2026, the count stands at 1 purchase and no sales.

On 17 July 2026 came the latest disclosure, a share grant in Vaxart, Inc. The most recent open-market purchase was published on 7 January 2026, 284 days ago. The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.